| 
| ||||||||||||||
- Description
- Disease & phenotype
- Genes & alleles
- Genotyping
- Health & care
- References
- Pricing & purchasing
- Terms of use
Description
The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.
Strain Information
Former Names B6.129(Cg)-Cd44tm1Hbg/SjJ (Changed: 28-APR-10 ) B6.Cg-Cd44tm1Hbg/SjJ (Changed: 28-APR-10 ) Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Donating Investigator Simon John, JAX Description
Mice that are homozygous for the targeted mutation are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. No gene product (mRNA or protein) is detected. Although lymphocyte development appears unremarkable, irregularities are observed in lymphocyte trafficking. Tail-injected lymphocytes derived from null animals exhibit an impaired ability to traffic to peripheral lymph nodes, and to a much greater degree, the thymus. Transcription and translation of the targeted allele subsequently lead to the synthesis of the lacZ protein under control of the 5' regulatory elements of the endogenous locus in all cells and tissues normally expressing one or several of the CD44 isoforms.In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.
Development
A targeting vector containing a neomycin resistance/lacZ cassette was used to disrupt exon1 and a portion of intron 1 resulting in total loss of Cd44 transcription. Endogenous Cd44 regulatory elements direct the transcription of the inserted neo/lacZ cassette. The construct was electroporated into 129-derived R1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts. The resulting chimeric animals were backcrossed to C57BL/6. After arrival at The Jackson Laboratory (as Stock No. 003899), SNP analysis suggested that the strain had at least one other unidentified strain in its genetic background. These mixed background were mice were then backcrossed to C57BL/6J inbred mice for at least 5 generations to generate the congenic strain B6.Cg-Cd44tm1Hbg/J (Stock No. 005085). The Cd44tm1Hbg allele from Stock No. 005085 was further backcrossed onto C57BL/6J in the laboratory of Dr. Simon John, reaching backcross generation N18 before cryopreservation of sperm.
Related Strains
lacZ Expression Strains
View lacZ Expression Strains (255 strains)
005085 B6.129(Cg)-Cd44tm1Hbg/J 005878 NOD.129(Cg)-Cd44tm1Hbg/J 003899 STOCK Cd44tm1Hbg/J
008008 SJL.129-Cd44tm1Ugu/J
Phenotype
Phenotype Information
assigned by genotype
Cd44tm1Hbg/Cd44tm1Hbg
B6.129-Cd44tm1Hbg
- hematopoietic system phenotype
- decreased mast cell histamine storage
- decreased histamine content in the peritoneal cavities and ear tissues (MGI Ref ID J:146846)
- decreased mast cell number
- immune system phenotype
- decreased mast cell histamine storage
- decreased histamine content in the peritoneal cavities and ear tissues (MGI Ref ID J:146846)
- decreased mast cell number
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Cd44tm1Hbg/Cd44tm1Hbg
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
- immune system phenotype
- abnormal CD4-positive T cell morphology
- CD4+ T cells do not have a CD25low+ population (MGI Ref ID J:68069)
- abnormal CD8-positive T cell morphology
- CD8+ T cells do not have a CD25low+ population (MGI Ref ID J:68069)
- abnormal leukocyte migration
- tail injected lymphocytes derived from homozygotes enter thymus 10-20 times less efficiently than controls (MGI Ref ID J:68069)
- migration to peripheral lymph nodes is delayed initially, but is balanced out in 24 hours (MGI Ref ID J:68069)
- lymphocyte migration to spleen is similar in mutant and control (MGI Ref ID J:68069)
- abnormal neutrophil physiology
- very few neutrophils emigrate from the venules after intrascrotal administration of MIP-2 chemokine (MGI Ref ID J:94850)
- normal circulating leukocyte numbers (MGI Ref ID J:94850)
- decreased neutrophil adhesion and emigration in response to MIP-2 (MGI Ref ID J:94850)
- normal ability of emigrated neutrophils to migrate through the tissue (MGI Ref ID J:94850)
- reduced neutrophil adhesion and emigration in chimeric mice whose endothelium lacks CD44 (MGI Ref ID J:94850)
- reduced emigration in chimeric mice whose leukocyte lacks CD44 (MGI Ref ID J:94850)
- hematopoietic system phenotype
- *normal* hematopoietic system phenotype
- cardiovascular system phenotype
- choroidal neovascularization
- vision/eye phenotype
- choroidal neovascularization
- cellular phenotype
- abnormal leukocyte migration
- tail injected lymphocytes derived from homozygotes enter thymus 10-20 times less efficiently than controls (MGI Ref ID J:68069)
- migration to peripheral lymph nodes is delayed initially, but is balanced out in 24 hours (MGI Ref ID J:68069)
- lymphocyte migration to spleen is similar in mutant and control (MGI Ref ID J:68069)
Cd44tm1Hbg/Cd44tm1Hbg
involves: 129S1/Sv * 129X1/SvJ
- immune system phenotype
- abnormal osteoclast differentiation
- trend towards decreased osteoclast surface in distal femur at the age of 17 weeks (MGI Ref ID J:101563)
- abnormal response to infection
- increased neutrophil accumulation in the lungs without compromising the control of bacterial growth (MGI Ref ID J:86947)
- neutrophils are prominent within alveoli and small conducting airways and bronchoalveolar lavages fluid, compared with the wild-type controls at day 20 after aerosol infection with low-dose M. tuberculosis (MGI Ref ID J:86947)
- lesions are more loosely organized than those from the wild-type group (MGI Ref ID J:86947)
- at day 30 postinfection, focal lesions begin to coalesce (MGI Ref ID J:86947)
- at day 65 postinfection, lesions are more severe and necrosis is greater than the wild-type (MGI Ref ID J:86947)
- increased acute inflammation
- limbs/digits/tail phenotype
- increased diameter of tibia
- short tibia
- shorter tibias (MGI Ref ID J:101563)
- integument phenotype
- abnormal epidermal lamellar body morphology
- reduced density of epidermal lamellar body (LB) in the cytosol of keratinocytes (MGI Ref ID J:108938)
- impaired skin barrier function
- a significant delay in barrier recovery kinetics at 1 hour after acute barrier disruption (MGI Ref ID J:108938)
- reduced secretion of lamellar material and delayed post-secretory dispersion of secreted lamellar material at stratum granulosum-stratum corneum (SG-SC) junction of epidermis at 1 hour after acute barrier disruption (MGI Ref ID J:108938)
- aberrant apical polarity of LB secretion towards the SG-SC interface (MGI Ref ID J:108938)
- redistributed from apical to basolateral membranes (MGI Ref ID J:108938)
- thin epidermis
- homeostasis/metabolism phenotype
- abnormal lipid level
- decreased total non-saponifiable lipid level in epidermis (MGI Ref ID J:108938)
- decreased cholesterol level
- decreased cholesterol level in epidermis (MGI Ref ID J:108938)
- altered response to myocardial infarction
- enhanced and prolonged neutrophil and macrophage infiltration in the infarct in comparison with wild-type (WT) animals (MGI Ref ID J:131974)
- decreased myofibroblast infiltration and reduced collagen deposition in the healing infarct (MGI Ref ID J:131974)
- slightly reduced percentage of apoptotic cells in comparison with WT mice after 72 h of reperfusion (MGI Ref ID J:131974)
- normal percentage of apoptotic cells after 24 h of reperfusion (MGI Ref ID J:131974)
- attenuated proliferative response in comparison to WT cardiac fibroblasts (MGI Ref ID J:131974)
- increased left ventricular end-diastolic volume and a trend toward lower left ventricular mass in comparison with WT animals after 7 days of reperfusion (MGI Ref ID J:131974)
- impaired skin barrier function
- a significant delay in barrier recovery kinetics at 1 hour after acute barrier disruption (MGI Ref ID J:108938)
- reduced secretion of lamellar material and delayed post-secretory dispersion of secreted lamellar material at stratum granulosum-stratum corneum (SG-SC) junction of epidermis at 1 hour after acute barrier disruption (MGI Ref ID J:108938)
- aberrant apical polarity of LB secretion towards the SG-SC interface (MGI Ref ID J:108938)
- redistributed from apical to basolateral membranes (MGI Ref ID J:108938)
- impaired wound healing
- decreased myofibroblast infiltration and reduced collagen deposition in the healing infarct (MGI Ref ID J:131974)
- slightly reduced percentage of apoptotic cells in comparison with WT mice after 72 h of reperfusion (MGI Ref ID J:131974)
- lower myofibroblast density in the infarcted myocardium after 3 days of reperfusion (MGI Ref ID J:131974)
- reduced proliferative activity in the infarcted myocardium (MGI Ref ID J:131974)
- reduced collagen content in the infarct compared with WT mice after 7 days of reperfusion (MGI Ref ID J:131974)
- skeleton phenotype
- abnormal osteoclast differentiation
- trend towards decreased osteoclast surface in distal femur at the age of 17 weeks (MGI Ref ID J:101563)
- increased diameter of tibia
- short tibia
- shorter tibias (MGI Ref ID J:101563)
- hematopoietic system phenotype
- abnormal osteoclast differentiation
- trend towards decreased osteoclast surface in distal femur at the age of 17 weeks (MGI Ref ID J:101563)
- cardiovascular system phenotype
- altered response to myocardial infarction
- enhanced and prolonged neutrophil and macrophage infiltration in the infarct in comparison with wild-type (WT) animals (MGI Ref ID J:131974)
- decreased myofibroblast infiltration and reduced collagen deposition in the healing infarct (MGI Ref ID J:131974)
- slightly reduced percentage of apoptotic cells in comparison with WT mice after 72 h of reperfusion (MGI Ref ID J:131974)
- normal percentage of apoptotic cells after 24 h of reperfusion (MGI Ref ID J:131974)
- attenuated proliferative response in comparison to WT cardiac fibroblasts (MGI Ref ID J:131974)
- increased left ventricular end-diastolic volume and a trend toward lower left ventricular mass in comparison with WT animals after 7 days of reperfusion (MGI Ref ID J:131974)
- cellular phenotype
- abnormal osteoclast differentiation
- trend towards decreased osteoclast surface in distal femur at the age of 17 weeks (MGI Ref ID J:101563)
This mouse can be used to support research in many areas including:Cd44tm1Hbg related
Cancer Research
Other
tumor metastasis
Cell Biology Research
Cell Motility Defects
Defects in Cell Adhesion Molecules
Developmental Biology Research
Defects in Cell Adhesion Molecules
Hematological Research
Immunological Defects
Immunology, Inflammation and Autoimmunity Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Inflammation
Lymphoid Tissue Defects
Lymphocyte Homing
Research Tools
Cancer Research
tumor immunology
Immunology and Inflammation Research
Internal/Organ Research
Genes & Alleles
Gene & Allele Information provided by MGI
| Allele Symbol | Cd44tm1Hbg | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Frank Hilberg | ||
| Allele Type | Targeted (Reporter) | ||
| Common Name(s) | CD44-; | ||
| Mutation Made By | Frank Hilberg, Boehringer Ingelheim R&D Vienna | ||
| Strain of Origin | (129X1/SvJ x 129S1/Sv)F1-Kitl<+> | ||
| ES Cell Line Name | R1 | ||
| ES Cell Line Strain | (129X1/SvJ x 129S1/Sv)F1-Kitl<+> | ||
| Site of Expression | lacZ expression is detected in all cells and tissues that normally express one or several CD44 isoforms. | ||
| Expressed Gene | lacZ, beta-galactosidase, E. coli | ||
| Molecular Note | A promoterless lacZ gene followed by a neomycin selection cassette was fused in frame directly following the translation start codon. Northern blot analysis on RNA derived from E13.5 homozygous embryos demonstrated that no wild-type transcript was detectable. Flow cytometry analysis on cells derived from thymus, spleen and lymph nodes of homozygous mice confirmed that no stable encoded protein was expressed on the cell surface. [MGI Ref ID J:68069] | ||
| Gene Symbol and Name | Cd44, CD44 antigen | ||
| Chromosome | 2 | ||
| Gene Common Name(s) | AU023126; AW121933; AW146109; CD44A; CDW44; CSPG8; ECMR-III; HCELL; HERMES; HUTCH-I; IN; LHR; Ly-24; MC56; MDU2; MDU3; METAA; MIC4; Pgp-1; Pgp1; RHAMM; expressed sequence AU023126; expressed sequence AW121933; expressed sequence AW146109; lymphocyte antigen 24; phagocyte glycoprotein 1; | ||
References
References provided by MGI
Additional References
Cd44tm1Hbg relatedAssimakopoulos D; Kolettas E; Patrikakos G; Evangelou A. 2002. The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas. Histol Histopathol 17(4):1269-81. [PubMed: 12371152] [MGI Ref ID J:79681]
Bollyky PL; Falk BA; Long SA; Preisinger A; Braun KR; Wu RP; Evanko SP; Buckner JH; Wight TN; Nepom GT. 2009. CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. J Immunol 183(4):2232-41. [PubMed: 19635906] [MGI Ref ID J:151479]
Bonder CS; Clark SR; Norman MU; Johnson P; Kubes P. 2006. Use of CD44 by CD4+ Th1 and Th2 lymphocytes to roll and adhere. Blood 107(12):4798-806. [PubMed: 16497973] [MGI Ref ID J:132863]
Bourguignon LY; Ramez M; Gilad E; Singleton PA; Man MQ; Crumrine DA; Elias PM; Feingold KR. 2006. Hyaluronan-CD44 interaction stimulates keratinocyte differentiation, lamellar body formation/secretion, and permeability barrier homeostasis. J Invest Dermatol 126(6):1356-65. [PubMed: 16557236] [MGI Ref ID J:108938]
Bradl H; Schuh W; Jack HM. 2004. CD44 is dispensable for B lymphopoiesis. Immunol Lett 95(1):71-5. [PubMed: 15325800] [MGI Ref ID J:110964]
Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP. 2005. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. J Bone Miner Res 20(1):30-40. [PubMed: 15619667] [MGI Ref ID J:101563]
Choi H; Lee RH; Bazhanov N; Oh JY; Prockop DJ. 2011. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-{kappa}B signaling in resident macrophages. Blood 118(2):330-8. [PubMed: 21551236] [MGI Ref ID J:174895]
Collins CB; Ho J; Wilson TE; Wermers JD; Tlaxca JL; Lawrence MB; Solga M; Lannigan J; Rivera-Nieves J. 2008. CD44 deficiency attenuates chronic murine ileitis. Gastroenterology 135(6):1993-2002. [PubMed: 18854186] [MGI Ref ID J:145626]
Crow AR; Song S; Suppa SJ; Ma S; Reilly MP; Andre P; McKenzie SE; Lazarus AH. 2011. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Blood 117(3):971-4. [PubMed: 21045192] [MGI Ref ID J:168394]
Flynn KM; Michaud M; Madri JA. 2013. CD44 deficiency contributes to enhanced experimental autoimmune encephalomyelitis: a role in immune cells and vascular cells of the blood-brain barrier. Am J Pathol 182(4):1322-36. [PubMed: 23416161] [MGI Ref ID J:195314]
Harrill AH; Watkins PB; Su S; Ross PK; Harbourt DE; Stylianou IM; Boorman GA; Russo MW; Sackler RS; Harris SC; Smith PC; Tennant R; Bogue M; Paigen K; Harris C; Contractor T; Wiltshire T; Rusyn I; Threadgill DW. 2009. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 19(9):1507-15. [PubMed: 19416960] [MGI Ref ID J:152633]
Hayer S; Steiner G; Gortz B; Reiter E; Tohidast-Akrad M; Amling M; Hoffmann O; Redlich K; Zwerina J; Skriner K; Hilberg F; Wagner EF; Smolen JS; Schett G. 2005. CD44 is a determinant of inflammatory bone loss. J Exp Med 201(6):903-14. [PubMed: 15781582] [MGI Ref ID J:97992]
Hidalgo A; Chang J; Jang JE; Peired AJ; Chiang EY; Frenette PS. 2009. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med 15(4):384-91. [PubMed: 19305412] [MGI Ref ID J:149370]
Hidalgo A; Peired AJ; Wild MK; Vestweber D; Frenette PS. 2007. Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity 26(4):477-89. [PubMed: 17442598] [MGI Ref ID J:123577]
Ho J; Kurtz CC; Naganuma M; Ernst PB; Cominelli F; Rivera-Nieves J. 2008. A CD8+/CD103high T cell subset regulates TNF-mediated chronic murine ileitis. J Immunol 180(4):2573-80. [PubMed: 18250468] [MGI Ref ID J:131978]
Huebener P; Abou-Khamis T; Zymek P; Bujak M; Ying X; Chatila K; Haudek S; Thakker G; Frangogiannis NG. 2008. CD44 is critically involved in infarct healing by regulating the inflammatory and fibrotic response. J Immunol 180(4):2625-33. [PubMed: 18250474] [MGI Ref ID J:131974]
Jong A; Wu CH; Gonzales-Gomez I; Kwon-Chung KJ; Chang YC; Tseng HK; Cho WL; Huang SH. 2012. Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection. J Biol Chem 287(19):15298-306. [PubMed: 22418440] [MGI Ref ID J:185462]
Kawana H; Karaki H; Higashi M; Miyazaki M; Hilberg F; Kitagawa M; Harigaya K. 2008. CD44 Suppresses TLR-Mediated Inflammation. J Immunol 180(6):4235-45. [PubMed: 18322236] [MGI Ref ID J:132955]
Khan AI; Kerfoot SM; Heit B; Liu L; Andonegui G; Ruffell B; Johnson P; Kubes P. 2004. Role of CD44 and hyaluronan in neutrophil recruitment. J Immunol 173(12):7594-601. [PubMed: 15585887] [MGI Ref ID J:94850]
Kipnis A; Basaraba RJ; Turner J; Orme IM. 2003. Increased neutrophil influx but no impairment of protective immunity to tuberculosis in mice lacking the CD44 molecule. J Leukoc Biol 74(6):992-7. [PubMed: 12972514] [MGI Ref ID J:86947]
Kirschner N; Haftek M; Niessen CM; Behne MJ; Furuse M; Moll I; Brandner JM. 2011. CD44 regulates tight-junction assembly and barrier function. J Invest Dermatol 131(4):932-43. [PubMed: 21191420] [MGI Ref ID J:180837]
Kodama K; Horikoshi M; Toda K; Yamada S; Hara K; Irie J; Sirota M; Morgan AA; Chen R; Ohtsu H; Maeda S; Kadowaki T; Butte AJ. 2012. Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc Natl Acad Sci U S A 109(18):7049-54. [PubMed: 22499789] [MGI Ref ID J:183933]
Krause DS; Lazarides K; von Andrian UH; Van Etten RA. 2006. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 12(10):1175-80. [PubMed: 16998483] [MGI Ref ID J:115161]
Larkin J; Renukaradhya GJ; Sriram V; Du W; Gervay-Hague J; Brutkiewicz RR. 2006. CD44 differentially activates mouse NK T cells and conventional T cells. J Immunol 177(1):268-79. [PubMed: 16785522] [MGI Ref ID J:134432]
McDonald B; Pittman K; Menezes GB; Hirota SA; Slaba I; Waterhouse CC; Beck PL; Muruve DA; Kubes P. 2010. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330(6002):362-6. [PubMed: 20947763] [MGI Ref ID J:164871]
Mochimaru H; Takahashi E; Tsukamoto N; Miyazaki J; Yaguchi T; Koto T; Kurihara T; Noda K; Ozawa Y; Ishimoto T; Kawakami Y; Tanihara H; Saya H; Ishida S; Tsubota K. 2009. Involvement of hyaluronan and its receptor CD44 with choroidal neovascularization. Invest Ophthalmol Vis Sci 50(9):4410-5. [PubMed: 19339747] [MGI Ref ID J:154560]
Morioka Y; Yamasaki K; Leung D; Gallo RL. 2008. Cathelicidin antimicrobial peptides inhibit hyaluronan-induced cytokine release and modulate chronic allergic dermatitis. J Immunol 181(6):3915-22. [PubMed: 18768846] [MGI Ref ID J:139105]
Murugaiyan G; Mittal A; Weiner HL. 2008. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 181(11):7480-8. [PubMed: 19017937] [MGI Ref ID J:142205]
Muto J; Yamasaki K; Taylor KR; Gallo RL. 2009. Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS. Mol Immunol 47(2-3):449-56. [PubMed: 19781786] [MGI Ref ID J:155232]
Nacher M; Blazquez AB; Shao B; Matesanz A; Prophete C; Berin MC; Frenette PS; Hidalgo A. 2011. Physiological Contribution of CD44 as a Ligand for E-Selectin during Inflammatory T-Cell Recruitment. Am J Pathol 178(5):2437-46. [PubMed: 21457936] [MGI Ref ID J:171380]
Protin U; Schweighoffer T; Jochum W; Hilberg F. 1999. CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J Immunol 163(9):4917-23. [PubMed: 10528194] [MGI Ref ID J:68069]
Riehl TE; Foster L; Stenson WF. 2012. Hyaluronic acid is radioprotective in the intestine through a TLR4 and COX-2-mediated mechanism. Am J Physiol Gastrointest Liver Physiol 302(3):G309-16. [PubMed: 22038822] [MGI Ref ID J:183323]
Takano H; Nakazawa S; Shirata N; Tamba S; Furuta K; Tsuchiya S; Morimoto K; Itano N; Irie A; Ichikawa A; Kimata K; Nakayama K; Sugimoto Y; Tanaka S. 2009. Involvement of CD44 in mast cell proliferation during terminal differentiation. Lab Invest 89(4):446-55. [PubMed: 19204665] [MGI Ref ID J:146846]
Taylor KR; Yamasaki K; Radek KA; Di Nardo A; Goodarzi H; Golenbock D; Beutler B; Gallo RL. 2007. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 282(25):18265-75. [PubMed: 17400552] [MGI Ref ID J:123387]
Velasco J; Li J; DiPietro L; Stepp MA; Sandy JD; Plaas A. 2011. Adamts5 deletion blocks murine dermal repair through CD44-mediated aggrecan accumulation and modulation of transforming growth factor beta1 (TGFbeta1) signaling. J Biol Chem 286(29):26016-27. [PubMed: 21566131] [MGI Ref ID J:175300]
Wang Y; Martin JF; Bai CB. 2010. Direct and indirect requirements of Shh/Gli signaling in early pituitary development. Dev Biol 348(2):199-209. [PubMed: 20934421] [MGI Ref ID J:166929]
Zarbock A; Lowell CA; Ley K. 2007. Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1. Immunity 26(6):773-83. [PubMed: 17543554] [MGI Ref ID J:123587]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.
Pricing and Purchasing
Pricing, Supply Level & Notes, Controls
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2250.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2925.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
|
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
Contact information
General inquiries regarding Terms of UseContracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.